IRVINGTON, N.Y., July 24, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced new study results demonstrating the effectiveness of MelaFind predictive probability information when used by dermatology residents. The results strongly correlate with the findings of a similar, previously reported analysis on dermatologists' decisions to biopsy. Together, these studies suggest the clinical impact of MelaFind predictive probability information (probability of lesion being melanoma and melanoma/high-grade) on...
↧